Head-to-head · WeighScore
Embody vs telos rx
By GLP-1 ScorecardUpdated
Score comparison
telos rx has the higher recorded score — 85.4/100 to 76.5/100.
telos rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telos offers compounded oral and injectable formats; discounted plans can carry early-exit adjustments.
Before you choose
Before comparing the headline prices, the Embody review and the telos rx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Embody vs Trimi and EmbraceRX vs telos rx compare each of them with another graded program, and the list of alternatives to Embody ranks the programs closest to Embody on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Strut Health review covers one graded close to these two, at 79.4/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Embody | telos rx |
|---|---|---|
| WeighScore | 76.5/100 | 85.4/100 |
| Grade | C | B |
| Site position | #52 | #13 |
| Semaglutide | $79/mo (monthly plan; twelve-month bundle listed at $49/mo, upfront charge unpublished) | Advertised from $99/month injectable; plan-dependent; selected bill unverified. |
| Tirzepatide | $129/mo (monthly plan; twelve-month bundle listed at $99/mo, upfront charge unpublished) | Advertised from $139/month injectable; from $116/month microdosed injection; selected bills unverified. |
| Coverage | State eligibility not fully published; confirm your location | Advertises all 50 states; pharmacy and formulation availability varies. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Strengths
- Monthly plans at $79 semaglutide and $129 tirzepatide in the published terms
- Separate monthly, three-, six- and twelve-month price tiers published
- OpenLoop care network and four pharmacy partners publicly named; individual assignment still needs confirmation
What to consider
- Payments are described as final at purchase except provider-initiated medical disqualification, with used services deducted
- Cancel at least 72 hours before renewal; unused prepaid months are not routinely refundable
- Homepage week counts differ from product month labels; confirm supply and charge dates
- Current catalog supports injections; no active oral-gum offer or universal state footprint confirmed
Strengths
- Names its care organization and pharmacy partners
- Oral and injectable compounded options
What to consider
- Early cancellation can reprice supplied months
- Entity, denial-refund and lab terms conflict
- Current oral invoice and renewal price unverified
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.